BiondVax Pharmaceuticals - ADR Financials

$0.69

$0.05 (7.81%)

As on 08-Nov-2023 09:30EDT

Market cap

$5 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

7.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	2.02	--	2.75	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	2.02	--	2.75	--	--	--
Operating Expenses	12.32	11.06	34.83	-2.28	78.35	20.46
Operating Profit (EBIT)	-12.32	-11.06	-34.83	1.04	-78.35	-20.46
Other Income	--	--	--	--	--	--
Profit before Tax	-1.21	-5.80	-39.98	-1.39	-109.19	-23.29
Provision for Tax	-18.59	-5.27	10.83	-8.20	14.92	2.89
Profit after Tax (Net Income)	17.22	-0.53	-50.81	6.82	-124.11	-23.29
Minority Interest	--	--	--	--	--	--
Consolidated Profit	3.75	--	-39.98	-4.46	-109.19	-87.73

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	-7.11	-1.76	23.33	-4.54	-65.05	-8.29
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	25.12	26.49	69.06	2.28	161.84	30.60
Current Liabilities	1.89	2.34	7.21	19.96	18.96	5.79
Total Liabilities	21.79	27.07	99.60	17.70	115.75	28.10

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	12.13	12.70	44.55	14.39	42.63	7.70
Current Assets	7.77	14.37	55.05	3.30	73.12	20.40
Total Assets	21.79	27.07	99.60	17.70	115.75	28.10
Total Debt*	24.61	21.54	69.74	20.89	131.28	94.36
Net Current Assets	5.88	12.03	47.84	-53.56	54.16	55.05

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-7.27	-24.48	-72.54	-77.06	-57.19
Cash Flow from Investing Activities	--	--	-0.36	-5.94	-7.20	-23.45
Cash from Financing Activities	--	6.78	67.78	13.72	85.21	84.32
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-0.94	-92.87	16.51	-162.98	-32.73
ROE (%)	--	-4.92	-540.71	-19.59	338.45	-97.13
ROA (%)	26.32	-0.84	-86.63	10.21	-172.56	-42.43
EBIT Margin (%)	-618.44	--	-1,267.43	--	--	--
Net Margin (%)	854.38	--	-1,848.98	--	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	-26.64	-1.00	--	--	--	--
EBIT Growth (%)	62.64	68.24	-3,449.19	101.33	-292.87	-56.50
Net Profit Growth (%)	141.72	98.95	-845.54	105.49	-432.82	32.58
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	--	--	--	--	--
Price / Book Value	7.48	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-2.07	-0.71	-0.48	5.17	-0.77	-3.77
Close Price ($)	1.41	2.96	23.50	28.10	92.90	47.70
High Price ($)	99.00	99.00	72.20	620.00	93.90	77.13
Low Price ($)	1.29	2.83	13.60	23.50	44.30	35.10
Market Cap ($ Cr)	4.97	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	-3.28	-12.24	2.99	-4.60	-2.02	-11.38
Short term debt to equity ratio	-0.06	-0.22	0.03	-4.18	-0.01	--
Current Ratio	4.12	6.15	7.64	0.17	3.86	3.53
Quick Ratio	4.12	--	--	--	--	3.63
Interest Coverage	0.93	-2.10	-3.22	0.21	-5.25	-5.52

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	6.85	--	11.14	--	--	--
Asset Turnover	0.03	--	0.05	--	--	--
Receivable days	--	--	45.22	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.